Startups
Moleac is a biopharmaceutical company that stays committed to helping patients and their families reconnect with their lives. We address unmet needs of patients suffering a loss of brain function after brain injuries or neurodegenerative diseases. Our focus is to help them regain and maintain independence. We select scientifically proven natural compounds and formulations with origins in traditional medicine, establish their clinical properties, and make them available internationally.
Overview
Location
Singapore
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 1, 2025 | Indonesia’s Adivira Capital in talks to invest in SG biopharma firm | Indonesian private equity firm Adivira Capital is said to be in discussions to invest in Moleac, a Singapore-based biopharmaceutical company, according to sources familiar with the matter. |
| Oct 21, 2024 | Moleac Announces PT Ferron Par Pharmaceuticals as New Exclusive Partner in Indonesia | SINGAPORE, Oct. 21, 2024 /PRNewswire/ -- Moleac is excited to announce a significant milestone in the journey of NeuroAiD II MLC901 as PT Ferron Par Pharmaceuticals will become our exclusive partner in Indonesia effective Jan 1st 2025. We a... |
| Jun 6, 2022 | NeuroAiD has shown favourable outcome in patients suffering from spinal cord injuries | SATURN study aimed at assessing the safety and effects of a 6-month course of NeuroAiD (MLC601/MLC901) to augment functional and motor recovery after severe spinal cord injury (SCI). NeuroAiD was safe as add-on treatment in patients with se... |
| Jan 13, 2022 | NeuroAiD(TM)II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression | SINGAPORE, Jan. 13, 2022 /PRNewswire/ -- Moleac is pleased to announce the release of the ATHENE study results, published in the Journal of the American Medical Director Association (JAMDA)1. Alzheimer's Disease (AD) and other dementias cau... |
| May 31, 2021 | Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Traumatic Brain Injury Recovery | SINGAPORE, May 31, 2021 /PRNewswire/ -- Moleac, a biopharmaceutical company based in Singapore, announced the approval by the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for MLC1501 in traumatic ... |
| May 6, 2021 | Moleac Pte Ltd wins SBR National Business Award for Pharmaceuticals | SINGAPORE, May 6, 2021 /PRNewswire/ -- Moleac, a biopharmaceutical company based in Singapore, wins SBR National Business Award for Pharmaceuticals. Moleac is dedicated in finding, developing and commercialising new medicines for the unmet ... |
Reviews 0
FAQ about moleac.com
What has the press written about moleac.com?
Parsers VC has collected 7 articles mentioning moleac.com, among them “Indonesia’s Adivira Capital in talks to invest in SG biopharma firm” (May 1, 2025) and “Moleac Announces PT Ferron Par Pharmaceuticals as New Exclusive Partner in Indonesia” (Oct 21, 2024).
Is moleac.com still active?
Yes, moleac.com is active; its latest activity on Parsers VC dates from Feb 5, 2026.